NCT06828289Not yet recruiting
Rivastigmine Mini-Tablet for Alzheimer's Disease
Observational Study of Rivastigmine Mini-Tablet in Patients with Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 20 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The objective of this study is to evaluate the efficacy and safety of rivastigmine mini-tablets in individuals diagnosed with mild to moderate Alzheimer's disease (AD).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 11 Feb 2025
- Start date
- 28 Feb 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Peking University First Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT06828289
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 28 Feb 2025 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects treated with medication for dementia two weeks prior to baseline
Other illness
- Any systemic or neurological condition that could contribute to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease
- Any psychiatric diagnosis or symptoms (hallucinations, major depression, delusions, etc) interfering with study procedures
- An advanced, severe or unstable disease of any type (cardiac, respiratory, gastrointestinal, renal disease, etc) that may interfere with efficacy evaluations
Who the study is looking for
- Age 50 or older
- Meet the National Institute of Aging-Alzheimer's Association clinical criteria for probable Alzheimer's disease
- Have a Mini-Mental State Examination score of 10 to 24 at Screening and Baseline
- Geriatric Depression Scale score \<=7 at Screening
- Hachinski Ischemic Scale \<=4 at Screening
- Brain MRI should meet: no infarcts in key areas (thalamus, hippocampus, entorhinal cortex, perirhinal cortex, angular gyrus, etc.), ≤ 2 stroke lesions \> 1.5 cm in diameter, and Fazekas Scale - assessed white matter lesion grade
- 2\.
- Patients whose caregivers are well-informed about the patients' condition and, if possible, live with them.
- Provide written informed consent
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.